Durham, NC-based Serenex has raised $30 million in its third round of venture capital. Serenex also announced that it has in-licensed worldwide rights to develop and commercialize SNX-1012 for chemotherapy and radiation-induced oral mucositis from Mucosal Therapeutics. Ritchie Capital led the round, which included existing investors Intersouth Partners, Lilly Ventures, Mediphase Venture Partners, Takeda Research Investment and Seaflower Ventures.
"This round of financing provides us with the resources to add to our development team, advance SNX-1012 through Phase 2 and move our internally developed novel Hsp90 inhibitor into Phase 1," said Serenex CEO Dr. Richard Kent.
- read this press release for more
ALSO: Canada's Topigen has added C$6 million to its second round. Release